tocilizumab · Actemra / RoActemra

Monoclonal antibody

Biosimilars tracked: BAT1806, CT-P47 (tocilizumab)

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, COVID-19

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (7)
US
  • ACTEMRA (tocilizumab), giant cell arteritis: Adult patients with giant cell arteritis.Outside this platform's coverage
  • ACTEMRA (tocilizumab), systemic sclerosis-associated interstitial lung disease: Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
  • ACTEMRA (tocilizumab), polyarticular juvenile idiopathic arthritis: Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis.Outside this platform's coverage
  • ACTEMRA (tocilizumab), systemic juvenile idiopathic arthritis: Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
  • ACTEMRA (tocilizumab), cytokine release syndrome: Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome.Outside this platform's coverage
Product first approved 2010FDA label
EU
  • Rheumatoid arthritis (RoActemra)
Product first approved 2009EMA
JP
  • Rheumatoid arthritis (Actemra, Chugai; earlier Japan approval for Castleman's disease in 2005)
Product first approved 2008manufacturingchemist.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (125)
COVID-19
NCT02735707 · UMC Utrecht
2016-04-11 – 2029-02 · Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
What this study did
NCT04424056 · Assistance Publique Hopitaux De Marseille
2020-09-01 – 2022-11-01 · Covid19
What this study did
NCT04600141 · University of Sao Paulo
2020-11-10 – 2021-12-31 · Covid19
What this study did
NCT04577534 · Jarmo Oksi
2020-08-14 – 2021-06-16 · Covid19
What this study did
NCT04423042 · University of Calgary
2020-07-30 – 2021-06 · Covid19, COVID-19, Severe Acute Respiratory Syndrome Coronavirus 2, Coronavirus, Inflammation
What this study did
NCT04330638 · University Hospital, Ghent
2020-04-03 – 2021-05-21 · COVID-19
What this study did
NCT04412772 · Queen's Medical Center
2020-06-12 – 2021-03-31 · COVID-19
What this study did
NCT04678739 · M Abdur Rahim Medical College and Hospital
2020-08-15 – 2021-02-10 · Covid19, Covid-19 ARDS
What this study did
NCT04345445 · University of Malaya
2020-04-15 – 2020-10-31 · COVID-19
What this study did
NCT04361032 · Abderrahmane Mami Hospital
2020-09-04 – 2020-10-04 · COVID19, Intensive Care Unit
What this study did
NCT04356937 · Massachusetts General Hospital
2020-04-20 – 2020-08-27 · SARS-CoV 2
What this study did
NCT04403685 · Beneficência Portuguesa de São Paulo
2020-05-08 – 2020-07-21 · COVID, SARS Pneumonia, Cytokine Release Syndrome
What this study did
NCT04361552 · Emory University
2020-04-07 – 2020-06-02 · Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure, Coronary Artery Disease, Diabetes Mellitus, Malignant Neoplasm, SARS Coronavirus 2 Infection
What this study did
Rheumatoid Arthritis
NCT06475508 · AO GENERIUM
2023-02-13 – 2024-06-11 · Rheumatoid Arthritis
What this study did
NCT05725434 · Celltrion
2023-02-06 – 2023-07-31 · Rheumatoid Arthritis
What this study did
NCT02837146 · Maria Stoenoiu
2015-12 – 2019-12 · Rheumatoid Arthritis
What this study did
NCT01668966 · Hoffmann-La Roche
2013-12-09 – 2016-05-11 · Rheumatoid Arthritis
What this study did
NCT01951170 · Hoffmann-La Roche
2013-11 – 2015-08 · Rheumatoid Arthritis
What this study did
NCT01655381 · Hoffmann-La Roche
2012-04 – 2015-07 · Rheumatoid Arthritis
What this study did
NCT01988012 · Hoffmann-La Roche
2014-01 – 2015-07 · Rheumatoid Arthritis
What this study did
NCT01664598 · Hoffmann-La Roche
2012-05 – 2015-06 · Rheumatoid Arthritis
What this study did
NCT01730456 · Hoffmann-La Roche
2012-10 – 2015-05 · Rheumatoid Arthritis
What this study did
NCT01665430 · Hoffmann-La Roche
2012-07 – 2015-02 · Rheumatoid Arthritis
What this study did
NCT01649804 · Hoffmann-La Roche
2012-07 – 2014-12 · Rheumatoid Arthritis
What this study did
NCT01245439 · Hoffmann-La Roche
2011-09 – 2014-08 · Rheumatoid Arthritis
What this study did
NCT01662063 · Genentech, Inc.
2012-08 – 2014-06 · Rheumatoid Arthritis
What this study did
NCT01007435 · Hoffmann-La Roche
2009-10-31 – 2014-01-28 · Rheumatoid Arthritis
What this study did
NCT01256736 · JW Pharmaceutical
2010-03 – 2013-11 · Rheumatoid Arthritis
What this study did
NCT01326962 · Hoffmann-La Roche
2011-11-30 – 2013-05-12 · Rheumatoid Arthritis
What this study did
NCT01347983 · Chugai Pharma Taiwan
2011-05 – 2013-04 · Rheumatoid Arthritis
What this study did
Phase 2/3 (10)
COVID-19
NCT04347031 · Burnasyan Federal Medical Biophysical Center
2020-04-08 – 2020-11-20 · Pneumonia, Viral, Respiratory Failure
What this study did
NCT04349410 · The Camelot Foundation
2020-04-11 – 2020-09-14 · CoVid 19 Positive
What this study did
Other / comorbidity
NCT07570173 · Merck Sharp & Dohme LLC
2026-05-18 – 2033-10-18 · B-cell Acute Lymphoblastic Leukemia
What this study did
NCT07870681 · Oslo University Hospital
2026-09-21 – 2030-01-31 · Acute Ischemic Stroke
What this study did
NCT06452537 · Tianjin Medical University General Hospital
2024-07-09 – 2026-07-01 · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
What this study did
NCT05716035 · Tang-Du Hospital
2023-04-01 – 2024-12-31 · Myasthenia Gravis, Generalized
What this study did
NCT06238024 · Suzhou Municipal Hospital of Anhui Province
2024-02-02 – 2024-09-22 · Interleukin-6, Ischemic Stroke, Endovascular Treatment
What this study did
NCT03353259 · Oslo University Hospital
2017-11-28 – 2021-09-01 · Chronic Subdural Hematoma
What this study did
NCT03350633 · Tianjin Medical University General Hospital
2017-11-01 – 2019-09-01 · Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica
What this study did
NCT01782235 · University Hospital, Strasbourg, France
2013-07-24 – 2018-07-16 · Primary Sjögren's Syndrome (pSS)
What this study did
Phase 2 (106)
COVID-19
NCT04363853 · Instituto Nacional de Cancerologia de Mexico
2020-06-01 – 2027-12-31 · Sars-CoV2
What this study did
NCT04479358 · University of Chicago
2020-09-10 – 2025-02-10 · COVID-19
What this study did
NCT04321993 · Lisa Barrett
2020-04-17 – 2024-04 · COVID-19
What this study did
NCT04317092 · National Cancer Institute, Naples
2020-03-19 – 2023-12-19 · COVID-19 Pneumonia
What this study did
NCT04377659 · Memorial Sloan Kettering Cancer Center
2020-05-01 – 2022-10-28 · COVID-19
What this study did
NCT04476979 · Assistance Publique - Hôpitaux de Paris
2020-07-16 – 2021-08-11 · Coronavirus Infection, SARS (Severe Acute Respiratory Syndrome), Virus Diseases, Coronaviridae Infections, Nidovirales Infections, RNA Virus Infections, Respiratory Tract Infections, Respiratory Tract Disease
What this study did
NCT04332094 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2020-04-02 – 2021-07 · COVID-19
What this study did
NCT04335305 · MedSIR
2020-04-09 – 2021-06-21 · COVID-19, Pneumonia, Viral
What this study did
NCT04435717 · Hospital Universitario Ramon y Cajal
2020-05-04 – 2021-02-10 · Covid19
What this study did
NCT04370834 · National Cancer Institute (NCI)
2020-05-28 – 2021-01-14 · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
What this study did
NCT04339712 · Hellenic Institute for the Study of Sepsis
2020-04-02 – 2021-01-08 · COVID-19, Virus Diseases, Macrophage Activation Syndrome, Corona Virus Infection
What this study did
NCT04445272 · Fundacion SEIMC-GESIDA
2020-05-22 – 2020-12-23 · COVID-19
What this study did
NCT04377503 · Hospital Sao Domingos
2020-05-01 – 2020-11-30 · Cytokine Release Syndrome, Covid-19
What this study did
NCT04322773 · Marius Henriksen
2020-04-05 – 2020-10-08 · Corona Virus Disease
What this study did
NCT04335071 · Insel Gruppe AG, University Hospital Bern
2020-04-26 – 2020-09-27 · SARS-CoV-2 Infection
What this study did
NCT04363736 · Hoffmann-La Roche
2020-05-05 – 2020-08-12 · COVID-19 Pneumonia
What this study did
NCT04346355 · Azienda USL Reggio Emilia - IRCCS
2020-03-31 – 2020-06-06 · COVID-19 Pneumonia
What this study did
NCT04331795 · University of Chicago
2020-04-04 – 2020-06-05 · COVID-19
What this study did
NCT04315480 · Università Politecnica delle Marche
2020-03-12 – 2020-05 · SARS Pneumonia
What this study did
Rheumatoid Arthritis
NCT00887341 · Hoffmann-La Roche
2009-05 – 2010-12 · Rheumatoid Arthritis
What this study did
NCT00144651 · Chugai Pharmaceutical
2001-08 – 2009-06 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05833763 · Australasian Leukaemia and Lymphoma Group
2023-10-12 – 2037-04 · Mantle Cell Lymphoma, Mantle Cell Lymphoma Refractory
What this study did
NCT07709000 · Merck Sharp & Dohme LLC
2026-10-14 – 2033-11-16 · Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies
What this study did
NCT06043674 · Christine Ryan
2024-01-22 – 2033-01-15 · Chronic Lymphocytic Leukemia, Richter's Transformation
What this study did
NCT06381661 · Assistance Publique - Hôpitaux de Paris
2026-07-09 – 2031-07-09 · Sepsis
What this study did
NCT07493317 · Icahn School of Medicine at Mount Sinai
2026-03-26 – 2031-02-06 · Major Depressive Disorder
What this study did
NCT07825064 · Hoffmann-La Roche
2026-11-03 – 2031-01-19 · Multiple Myeloma
What this study did
NCT07589634 · Janssen Research & Development, LLC
2026-06-30 – 2030-07-30 · Multiple Myeloma
What this study did
NCT07637578 · SCRI Development Innovations, LLC
2026-09-01 – 2030-02 · Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple Myeloma
What this study did
NCT07108387 · National Institute of Allergy and Infectious Diseases (NIAID)
2026-01-05 – 2030-01-11 · Giant Cell Arteritis (GCA)
What this study did
NCT05233397 · Nationwide Children's Hospital
2022-12-16 – 2029-12 · Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
What this study did
NCT07254637 · Assistance Publique - Hôpitaux de Paris
2026-11 – 2029-11 · Calcium Pyrophosphate Deposition Disease
What this study did
NCT07774247 · CHA University
2026-09-01 – 2029-09-01 · Hepatocellular Carcinoma (HCC)
What this study did
NCT03787290 · Massachusetts General Hospital
2026-12-01 – 2029-03-01 · Major Depressive Disorder
What this study did
NCT06033196 · National Institute of Allergy and Infectious Diseases (NIAID)
2024-02-13 – 2029-01-08 · Lung Transplant
What this study did
NCT07052058 · Hospital de Clinicas de Porto Alegre
2026-07-01 – 2028-07-01 · Treatment-Resistant Major Depressive Disorder
What this study did
NCT04554771 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2021-01-27 – 2028-04-10 · Esophageal Adenocarcinoma, Oesophageal Adenocarcinoma, Resectable Carcinoma
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT06941376 · University of Pennsylvania
2025-11-11 – 2027-12 · Relapsing Polychondritis
What this study did
NCT05846789 · Kathy Miller
2024-07-02 – 2027-12 · Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast Cancer
What this study did
NCT05207670 · Genentech, Inc.
2022-02-01 – 2027-10-29 · Non-Hodgkin Lymphoma
What this study did
NCT05972135 · SCRI Development Innovations, LLC
2023-10-23 – 2027-10 · Multiple Myeloma
What this study did
NCT04729959 · National Cancer Institute (NCI)
2022-03-11 – 2027-08-20 · Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
What this study did
NCT03708224 · Alain Algazi
2019-03-08 – 2027-07-31 · Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
What this study did
NCT05874505 · Assistance Publique - Hôpitaux de Paris
2023-07 – 2027-07 · Behcet's Uveitis
What this study did
NCT05845723 · Peking Union Medical College Hospital
2023-06-01 – 2027-06-01 · Aneurysm, Behcet Syndrome, Vascular Type
What this study did
Phase 1/2 (37)
Rheumatoid Arthritis
NCT04842981 · University of Southern Denmark
2021-05-25 – 2022-09-30 · Arthritis, Rheumatoid, Interaction
What this study did
Other / comorbidity
NCT05533775 · Hoffmann-La Roche
2022-11-16 – 2032-11-30 · Mature B-Cell Non-Hodgkin Lymphoma
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT07889232 · VA Office of Research and Development
2026-12-07 – 2029-11-30 · Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers
What this study did
NCT07113743 · National Institute of Allergy and Infectious Diseases (NIAID)
2025-09-10 – 2029-09-01 · Chronic Granulomatous Disease (CGD)
What this study did
NCT07595900 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06-01 – 2028-10-30 · Granulomatous Lobular Mastitis, Granulomatous Mastitis
What this study did
NCT05583617 · Hoffmann-La Roche
2023-11-14 – 2028-07-31 · Multiple Myeloma
What this study did
NCT03867617 · Thomas Wekerle
2019-08-01 – 2028-06 · Kidney Transplantation
What this study did
NCT04524871 · Hoffmann-La Roche
2020-11-01 – 2027-09-30 · Advanced Liver Cancers
What this study did
NCT04691817 · Abramson Cancer Center at Penn Medicine
2023-07-25 – 2027-09 · Lung Cancer, Nonsmall Cell
What this study did
NCT03564340 · Regeneron Pharmaceuticals
2018-05-21 – 2027-05-10 · Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
What this study did
NCT05535244 · Hoffmann-La Roche
2022-10-17 – 2027-02-26 · Multiple Myeloma
What this study did
NCT03533283 · Hoffmann-La Roche
2018-05-08 – 2026-10-22 · Non-Hodgkins Lymphoma
What this study did
NCT03869190 · Hoffmann-La Roche
2019-06-01 – 2025-12-22 · Urothelial Carcinoma, Bladder Cancer
What this study did
NCT03337698 · Hoffmann-La Roche
2017-12-27 – 2025-11-25 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT03467256 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2018-05-14 – 2025-10-15 · B-cell Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Pediatric
What this study did
NCT03671018 · Hoffmann-La Roche
2018-09-25 – 2025-07-20 · B-cell Non-Hodgkin Lymphoma
What this study did
NCT03193190 · Hoffmann-La Roche
2017-07-05 – 2025-02-27 · Pancreatic Adenocarcinoma
What this study did
NCT05070247 · Takeda
2022-04-14 – 2025-01-06 · Pancreatic Cancer, Hepatocellular Cancer, Mesothelioma, Breast Cancer, Gastric Cancer, Esophageal Cancer, Nasopharyngeal Cancer, Kidney Cancer, Squamous Cell Cancer of Head and Neck (SCCHN), Non-small Cell Lung Cancer (NSCLC), Non-squamous
What this study did
NCT04066114 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-12-11 – 2023-09-14 · Living-Donor Kidney Transplant, Kidney Transplant Recipients
What this study did
NCT02348216 · Kite, A Gilead Company
2015-04-21 – 2023-07-27 · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
What this study did
NCT02997956 · University of Michigan Rogel Cancer Center
2017-07 – 2022-07 · Hepatocellular Carcinoma
What this study did
NCT03745586 · Insel Gruppe AG, University Hospital Bern
2018-12-01 – 2021-03-01 · Giant Cell Arteritis
What this study did
NCT03533101 · Hospital Universitario Dr. Jose E. Gonzalez
2018-05-25 – 2019-06-15 · Cytokine Release Syndrome, Stem Cell Transplant Complications
What this study did
NCT01475162 · Medical College of Wisconsin
2011-08-08 – 2018-09-29 · Acute Graft Versus Host Disease
What this study did
NCT03062579 · Fu-Dong Shi
2017-02-01 – 2018-05-15 · Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica, Devic's Disease
What this study did
NCT01717170 · University of Nebraska
2013-03 – 2017-12 · Intermediate Uveitis, Posterior Uveitis, Pan-uveitis
What this study did
NCT02049437 · Case Western Reserve University
2014-08 – 2017-09-11 · HIV Infections
What this study did
NCT01603355 · Eric B. Suhler
2013-11 – 2016-02 · Juvenile Idiopathic Arthritis Associated Uveitis
What this study did
NCT01594424 · Cedars-Sinai Medical Center
2012-06 – 2015-05 · End Stage Renal Disease (ESRD)
What this study did
NCT01637532 · Leiden University Medical Center
2011-02 – 2013-09 · Recurrent Ovarian Cancer
What this study did
Phase 1 (73)
COVID-19
NCT05925140 · Lebanese University
2020-03-28 – 2025-12-30 · COVID-19, Hospitalized COVID-19 Patients
What this study did
NCT05164133 · Hoffmann-La Roche
2022-06-10 – 2024-03-27 · COVID-19
What this study did
NCT05118737 · Hamad Medical Corporation
2021-10-01 – 2022-08-30 · COVID-19 Pneumonia
What this study did
NCT04560205 · Lahore General Hospital
2020-05-01 – 2020-12-30 · SARS-CoV Infection
What this study did
Rheumatoid Arthritis
NCT05869955 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2023-09-13 – 2028-08-29 · Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
What this study did
NCT04885829 · Syneos Health
2021-05-31 – 2023-05-04 · Rheumatoid Arthritis, Giant Cell Arteritis
What this study did
NCT03606876 · Bio-Thera Solutions
2018-06-13 – 2019-07-17 · Rheumatoid Arthritis
What this study did
NCT00965653 · Hoffmann-La Roche
2009-08 – 2011-07 · Rheumatoid Arthritis
What this study did
NCT00365001 · Hoffmann-La Roche
est. completion 2008-04 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07594067 · University of Pennsylvania
2026-12 – 2042-11 · Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Adenocarcinoma
What this study did
NCT05091424 · Hoffmann-La Roche
2022-03-07 – 2032-02-10 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT07573332 · University of Texas Southwestern Medical Center
2026-09-01 – 2031-08-01 · AQP4+ NMOSD
What this study did
NCT07870278 · Merck Sharp & Dohme LLC
2026-11-13 – 2031-07-07 · Ovarian Neoplasms, Endometrial Neoplasms
What this study did
NCT07838974 · University of Southern California
2026-11-01 – 2030-11-01 · Melanoma
What this study did
NCT07115745 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2025-09-04 – 2030-08-16 · Refractory Autoimmune Diseases
What this study did
NCT07392814 · Nantes University Hospital
2026-03-10 – 2030-07-10 · Leukemia Acute Myeloid - AML
What this study did
NCT07708038 · Boston Medical Center
2027-09 – 2030-06 · Calciphylaxis
What this study did
NCT07629583 · Genentech, Inc.
2026-11-02 – 2030-03-29 · Lupus Erythematosus, Systemic
What this study did
NCT04910568 · Genentech, Inc.
2021-07-26 – 2028-12-21 · Multiple Myeloma
What this study did
NCT06934044 · Hoffmann-La Roche
2025-05-13 – 2028-11-15 · Multiple Myeloma
What this study did
NCT06863480 · University of Florida
2026-03-02 – 2028-10-30 · Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
What this study did
NCT04007029 · Jonsson Comprehensive Cancer Center
2019-10-04 – 2028-08-01 · CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT05391750 · Emory University
2022-10-19 – 2028-02-12 · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
What this study did
NCT06372574 · Genentech, Inc.
2024-09-30 – 2028-02-01 · Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult
What this study did
NCT04616248 · University of Southern California
2023-01-09 – 2028-01-09 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
What this study did
NCT05835986 · Hoffmann-La Roche
2023-12-18 – 2027-11-30 · Systemic Lupus Erythematosus
What this study did
NCT05927571 · Genentech, Inc.
2023-08-10 – 2027-07-31 · Relapsed or Refractory Multiple Myeloma
What this study did
NCT03970226 · University of Colorado, Denver
2019-09-16 – 2027-05 · Adamantinomatous Craniopharyngioma
What this study did
NCT03448042 · Genentech, Inc.
2018-06-06 – 2027-04-30 · Solid Tumors
What this study did
NCT06624085 · Hoffmann-La Roche
2025-04-28 – 2027-03-22 · Lymphoma
What this study did
NCT06016179 · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
2024-01-30 – 2027-01 · Malignant Pleural Effusion, Malignant Ascites
What this study did
NCT05646836 · Genentech, Inc.
2023-03-21 – 2026-11-18 · Multiple Myeloma
What this study did
NCT03275103 · Genentech, Inc.
2017-09-19 – 2026-01-07 · Multiple Myeloma
What this study did
NCT06488521 · AO GENERIUM
2024-06-20 – 2025-07-28 · Healthy Volunteers
What this study did
NCT05333302 · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
2020-10-26 – 2025-06 · B-cell Acute Lymphoblastic Leukemia, Lymphoblastic B-Cell Lymphoma
What this study did
NCT05619744 · Hoffmann-La Roche
2023-01-23 – 2025-03-04 · Small Cell Lung Cancer, Neuroendocrine Carcinoma
What this study did
NCT05769959 · Hoffmann-La Roche
2023-06-15 – 2024-03-19 · Renal Cell Carcinoma, Non-small Cell Lung Cancer, Pancreatic Adenocarcinoma, Colorectal Cancer, Ovarian Neoplasms
What this study did
NCT02874573 · Brian Miller
2016-09 – 2023-12-31 · Schizophrenia, Psychotic Disorders
What this study did
NCT04580121 · Hoffmann-La Roche
2020-11-04 – 2023-08-09 · Acute Myeloid Leukemia
What this study did
NCT04547062 · Nantes University Hospital
2020-12-29 – 2023-04-04 · Acute Myeloid Leukemia (AML)
What this study did
Phase 4 (57)
COVID-19
NCT04377750 · Hadassah Medical Organization
2020-04-08 – 2021-05-08 · Covid19 Pneumonia
What this study did
NCT04779047 · October 6 University
2020-10-01 – 2021-04-05 · Covid19, Pneumonia
What this study did
NCT05133635 · Marmara University
2021-02-01 – 2021-04-01 · COVID-19 Virus Infection, Cytokine Storm, Corticosteroid, Tocilizumab
What this study did
NCT04730323 · FMH College of Medicine and Dentistry
2020-05-12 – 2020-06-12 · Covid19
What this study did
Rheumatoid Arthritis
NCT07643038 · Chinese SLE Treatment And Research Group
2026-09-20 – 2029-07-31 · Rheumatoid Arthritis Associated Interstitial Lung Disease
What this study did
NCT07582185 · Centre Hospitalier Universitaire de Nice
2026-06-01 – 2026-12-31 · Rheumatoid Arthritis
What this study did
NCT03227419 · Lille Catholic University
2018-01-22 – 2026-01-29 · Arthritis, Rheumatoid
What this study did
NCT02765074 · Centre Hospitalier Régional d'Orléans
2016-06-30 – 2025-04-03 · Rheumatoid Arthritis
What this study did
NCT03895879 · Reade Rheumatology Research Institute
2020-03-01 – 2024-12 · Rheumatoid Arthritis
What this study did
NCT01491815 · Karolinska Institutet
2012-12-14 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT02466581 · Karolinska Institutet
2015-02-03 – 2023-12 · Rheumatoid Arthritis
What this study did
NCT03100253 · Mario Negri Institute for Pharmacological Research
2018-03-01 – 2021-12-31 · Rheumatoid Arthritis
What this study did
NCT03737708 · Astellas Pharma Korea, Inc.
2019-02-13 – 2020-06-16 · Rheumatoid Arthritis (RA)
What this study did
NCT03781310 · Tel-Aviv Sourasky Medical Center
2018-12 – 2019-12 · Rheumatoid Arthritis, Tocilizumab
What this study did
NCT02659150 · Massachusetts General Hospital
2016-05-18 – 2019-11-16 · Rheumatoid Arthritis
What this study did
NCT01557374 · Assistance Publique - Hôpitaux de Paris
2012-04 – 2019-11-08 · Rheumatoid Arthritis
What this study did
NCT02353780 · Dr. Larry W. Moreland
2015-03 – 2018-11-30 · Rheumatoid Arthritis (RA)
What this study did
NCT01638715 · Medical University of Vienna
2012-05 – 2018-08-01 · Rheumatoid Arthritis
What this study did
NCT02573012 · Hoffmann-La Roche
2016-03-29 – 2018-02-09 · Rheumatoid Arthritis
What this study did
NCT02843789 · Centre Hospitalier Universitaire de Besancon
2013-03 – 2017-11 · Arthritis, Rheumatoid
What this study did
NCT01717859 · University of California, Los Angeles
2014-09 – 2017-04 · Rheumatoid Arthritis
What this study did
NCT01752335 · Hospital Universitario de Canarias
2011-12 – 2017-03 · Rheumatoid Arthritis
What this study did
NCT02682823 · Hoffmann-La Roche
2016-03-21 – 2016-07-29 · Rheumatoid Arthritis
What this study did
NCT02087696 · Spanish Foundation of Rheumatology
2014-05 – 2016-07 · Arthritis, Rheumatoid
What this study did
NCT01715831 · Hoffmann-La Roche
2013-01-15 – 2016-06-06 · Arthritis, Rheumatoid
What this study did
NCT04157010 · University of Leeds
2013-05 – 2016-03-29 · Rheumatoid Arthritis
What this study did
NCT01120366 · SURPRISE Study Group
2009-10 – 2014-12 · Rheumatoid Arthritis
What this study did
NCT01251120 · Hoffmann-La Roche
2011-11 – 2013-01 · Rheumatoid Arthritis
What this study did
NCT01163747 · Genentech, Inc.
2010-09 – 2012-06 · Rheumatoid Arthritis
What this study did
NCT01119859 · Hoffmann-La Roche
2010-05 – 2012-01 · Rheumatoid Arthritis
What this study did
NCT01089023 · Hoffmann-La Roche
2010-01 – 2011-12 · Rheumatoid Arthritis
What this study did
NCT00996203 · Hoffmann-La Roche
2009-10-31 – 2011-02-14 · Rheumatoid Arthritis
What this study did
NCT02010216 · Hoffmann-La Roche
2010-03 – 2010-07 · Rheumatoid Arthritis
What this study did
NCT01010503 · Hoffmann-La Roche
2009-06 – 2010-05 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07609940 · Regeneron Pharmaceuticals
2026-07-15 – 2028-12-06 · Relapsed/Refractory Multiple Myeloma (RRMM)
What this study did
NCT06251076 · University Health Network, Toronto
2024-11-19 – 2026-10 · Multiple Myeloma, Relapsed Cancer, Refractory Cancer
What this study did
NCT06927375 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
2024-12-12 – 2026-03-12 · Thyroid-Associated Ophthalmopathy
What this study did
NCT06624436 · Radboud University Medical Center
2024-10-24 – 2025-12 · Sepsis, Neuroinflammatory Response, Immunosuppresion, Endotoxemia, Anakinra, Dexamethasone, Tocilizumab
What this study did
NCT05855122 · The First Affiliated Hospital of Soochow University
2023-04-17 – 2024-12-31 · Multiple Myeloma
What this study did
NCT05604859 · Qin Ning
2022-08-19 – 2024-06-30 · Severe Fever With Thrombocytopenia Syndrome
What this study did
Early phase / not applicable (26)
COVID-19
NCT05279391 · Democritus University of Thrace
2020-10-25 – 2023-12-31 · COVID-19 Severe Respiratory Failure
What this study did
NCT05082714 · University Hospital of Patras
2021-10-20 – 2022-06-04 · COVID-19
What this study did
NCT04394182 · Fundacion GenesisCare
2020-04-21 – 2022-03-21 · Pneumonia, Viral, Cytokine Storm
What this study did
NCT04690920 · University of Lahore
2020-07-23 – 2020-12-10 · Corona Virus Disease 2019 (COVID-19)
What this study did
NCT04519385 · South Valley University
2020-03-01 – 2020-08-05 · Pneumonia, Viral
What this study did
NCT04492501 · UNICEF
2020-04-01 – 2020-07-20 · Covid19, Cytokine Release Syndrome, Critical Illness, ARDS
What this study did
Rheumatoid Arthritis
NCT01245452 · Patrick Durez
2010-05 – 2013-06 · Rheumatoid Arthritis
What this study did
NCT00144573 · Chugai Pharmaceutical
2005-01 – 2005-10 · Rheumatoid Arthritis
What this study did
NCT00144560 · Chugai Pharmaceutical
2005-02 – 2005-08 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06654154 · University Hospital, Clermont-Ferrand
2024-04-03 – 2029-03 · Level of Serum Vitamin B12 Level (in Pmol/L) If Relapse of (AI/ID) Under Tocilizumab, Level of Serum Vitamin B12 Level (in Pmol/L) If Infection Under Tocilizumab
What this study did
NCT07801638 · Capital Medical University
2025-03-01 – 2028-09-30 · Cerebral Venous Thrombosis
What this study did
NCT07006532 · Shahid Beheshti University of Medical Sciences
2025-01-01 – 2027-05-01 · Kidney Transplant Rejection
What this study did
NCT07377058 · Peking Union Medical College Hospital
2025-11-01 – 2026-10 · Dermatomyositis
What this study did
NCT06721910 · University Hospital, Basel, Switzerland
2025-01-15 – 2025-09-18 · Healthy, Glucagon Resistance, Amino Acid Change
What this study did
NCT06442709 · Affiliated Hospital of Nantong University
2021-08-01 – 2024-07-01 · Nasopharyngeal Carcinoma
What this study did
NCT05349149 · Helga Ellingsgaard
2022-04-20 – 2022-10-11 · Glycogen Depletion
What this study did
NCT04616235 · Copenhagen University Hospital, Rigshospitalet
2021-03-15 – 2021-10-04 · Interleukin-6 Inhibition, Physical Stress, Appetitive Behavior
What this study did
NCT04687540 · Copenhagen University Hospital, Rigshospitalet
2021-04-09 – 2021-08-01 · Obesity, Healthy
What this study did
NCT03967691 · Copenhagen University Hospital, Rigshospitalet
2019-06-12 – 2020-04-03 · Obesity, Healthy
What this study did
NCT03601611 · Herlev Hospital
2019-01-01 – 2020-01-28 · Solid Tumor, Colitis, Arthritis
What this study did
NCT03507348 · University Hospital, Grenoble
2018-07-01 – 2019-11-21 · End-stage Renal Disease, Kidney Transplantation, Hla-incompatible Kidney Transplant Candidates
What this study did
NCT02901496 · Copenhagen University Hospital, Rigshospitalet
2016-08 – 2018-04 · Adiposity
What this study did
NCT02419937 · Keesler Air Force Base Medical Center
2015-05 – 2017-08 · Myocardial Infarction
What this study did
NCT01073826 · University of Zurich
2010-02 – 2016-06 · Diabetes Mellitus, Type 2, Obesity
What this study did
NCT01041248 · Children's Hospital of Eastern Ontario
2010-01 – 2012-01 · Relapsing Polychondritis
What this study did
NCT00868751 · Tufts Medical Center
2009-03 – 2010-06 · Arthritis, Juvenile Rheumatoid, Still's Disease, Juvenile Onset
What this study did
Used as active comparator (20)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (10)
COVID-19
NCT04693026 · M Abdur Rahim Medical College and Hospital
2020-09-10 – 2021-03-05 · Covid19, Covid-19 ARDS
What this study did
Rheumatoid Arthritis
NCT05090410 · Atsushi Kawakami
2021-03-03 – 2023-12-31 · Rheumatoid Arthritis, JAK Inhibitor, IL-6 Inhibitor, Musculoskeletal Ultrasound, Biomarker
What this study did
NCT05489224 · Celltrion
2022-09-14 – 2023-11-23 · Rheumatoid Arthritis
What this study did
NCT04512001 · Fresenius Kabi SwissBioSim GmbH
2020-08-03 – 2022-06-06 · Rheumatoid Arthritis
What this study did
NCT03830203 · Bio-Thera Solutions
2018-12-19 – 2021-01-05 · Rheumatoid Arthritis
What this study did
NCT01034137 · Hoffmann-La Roche
2010-01 – 2014-09 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04088396 · Eli Lilly and Company
2020-02-12 – 2026-10 · Systemic Juvenile Idiopathic Arthritis
What this study did
Phase 2 (3)
COVID-19
NCT04871854 · Beni-Suef University
2021-04-26 – 2022-08-26 · Breast Cancer
What this study did
Rheumatoid Arthritis
NCT02287922 · Ablynx, a Sanofi company
2015-03 – 2016-07 · Rheumatoid Arthritis
What this study did
Phase 1 (5)
Rheumatoid Arthritis
NCT05232396 · Beijing VDJBio Co., LTD.
2021-03-02 – 2022-02-25 · Rheumatoid Arthritis
What this study did
NCT02404558 · Sanofi
2015-05 – 2016-03 · Rheumatoid Arthritis
What this study did
NCT02097524 · Regeneron Pharmaceuticals
2014-03 – 2015-04 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05188378 · Celltrion
2021-12-22 – 2023-01-31 · Healthy Subjects
What this study did
NCT03282851 · Fresenius Kabi SwissBioSim GmbH
2017-11-27 – 2019-10-01 · Healthy
What this study did
Phase 4 (1)
Other / comorbidity
NCT04300686 · Shanghai Zhongshan Hospital
2020-03-01 – 2023-12-31 · Takayasu Arteritis, Tocilizumab, Adalimumab, Treatment
What this study did
Early phase / not applicable (1)
COVID-19
NCT04310228 · Peking University First Hospital
2020-03-08 – 2020-05 · COVID-19
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Phase 1/2 (1)
Other / comorbidity
NCT04082910 · Chinese PLA General Hospital
2019-09-15 – 2023-12-30 · Solid Tumor, Hematological Malignancy
What this study did
Phase 4 (1)
Rheumatoid Arthritis
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did
Early phase / not applicable (1)
COVID-19
NCT04380818 · Grupo de Investigación Clínica en Oncología Radioterapia
2020-06-05 – 2021-11-01 · Pneumonia, Viral
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tocilizumab (Actemra / RoActemra): this drugApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tofacitinib (Xeljanz)ApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
BMS-986454Phase 1—PAD4 (peptidylarginine deiminase 4)not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND261Phase 1Biologic (subtype unspecified)CD20 x CD3not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 63 furthest-along competitors are listed; 20 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(80 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Actemra / RoActemra (tocilizumab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (2)
Phase 2Behcet's UveitisNot yet recruiting
Est. primary completion 2026-11 · NCT05874505 · CT.gov ↗
What to watch
Phase 2Calcium Pyrophosphate Deposition DiseaseNot yet recruiting
Est. primary completion 2026-11 · NCT07254637 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Lung Cancer, Nonsmall CellRecruiting
Est. primary completion 2026-12 · NCT04691817 · CT.gov ↗
What to watch
Phase 2Myeloma, Lymphoma, LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06430736 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Acute Chest SyndromeRecruiting
Est. primary completion 2026-12 · NCT05640271 · CT.gov ↗
What to watch
Phase 2COVID-19Active not recruiting
Est. primary completion 2026-12-01 · NCT04363853 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-HodgkinActive not recruiting
Est. primary completion 2026-12-28 · NCT04077723 · CT.gov ↗
What to watch
2027 (28)
January 2027 (2)
Early phase / not applicableKidney Transplant RejectionRecruiting
Est. primary completion 2027-01-01 · NCT07006532 · CT.gov ↗
What to watch
Phase 1Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 …Active not recruiting
Est. primary completion 2027-01-09 · NCT04616248 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1Recurrent Plasma Cell Myeloma, Refractory Plasma Cell MyelomaActive not recruiting
Est. primary completion 2027-02-12 · NCT05391750 · CT.gov ↗
What to watch
Phase 2Acute Hypoxemic Respiratory FailureRecruiting
Est. primary completion 2027-02-20 · NCT07334379 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaActive not recruiting
Est. primary completion 2027-02-26 · NCT05535244 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT06624085 · CT.gov ↗
What to watch
April 2027 (4)
Phase 3Sickle Cell Disease, Acute Chest SyndromeRecruiting
Est. primary completion 2027-04 · NCT06818266 · CT.gov ↗
What to watch
Phase 3Ischemic StrokeRecruiting
Est. primary completion 2027-04-20 · NCT07509645 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-04-30 · NCT03448042 · CT.gov ↗
What to watch
Phase 2Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate CancerRecruiting
Est. primary completion 2027-04-30 · NCT03821246 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer …Recruiting
Est. primary completion 2027-05-10 · NCT03564340 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Giant Cell Arteritis (GCA)Recruiting
Est. primary completion 2027-06-11 · NCT07108387 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Relapsing PolychondritisRecruiting
Est. primary completion 2027-07 · NCT06941376 · CT.gov ↗
What to watch
Phase 1/2Advanced Liver CancersActive not recruiting
Est. primary completion 2027-07-30 · NCT04524871 · CT.gov ↗
What to watch
Phase 1Relapsed or Refractory Multiple MyelomaRecruiting
Est. primary completion 2027-07-31 · NCT05927571 · CT.gov ↗
What to watch
Phase 2Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck CancerActive not recruiting
Est. primary completion 2027-07-31 · NCT03708224 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-08 · NCT05972135 · CT.gov ↗
What to watch
Phase 1CD19 Positive, CD20 Positive, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma …Active not recruiting
Est. primary completion 2027-08-01 · NCT04007029 · CT.gov ↗
What to watch
Phase 3LymphomaRecruiting
Est. primary completion 2027-08-31 · NCT06084936 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2027-09-01 · NCT07774247 · CT.gov ↗
What to watch
October 2027 (2)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10-01 · NCT05207670 · CT.gov ↗
What to watch
Phase 4Relapsed/Refractory Multiple Myeloma (RRMM)Recruiting
Est. primary completion 2027-10-11 · NCT07609940 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-11-30 · NCT05835986 · CT.gov ↗
What to watch
December 2027 (5)
Phase 2Metastatic Breast Cancer, Triple Negative Breast Cancer, Estrogen-receptor-low Breast Cancer, ER Positive, HER2 Negative Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05846789 · CT.gov ↗
What to watch
Phase 2Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous CraniopharyngiomaActive not recruiting
Est. primary completion 2027-12 · NCT05233397 · CT.gov ↗
What to watch
Phase 3Giant Cell ArteritisActive not recruiting
Est. primary completion 2027-12 · NCT06037460 · CT.gov ↗
What to watch
Phase 3Systemic Sclerosis, Interstitial Lung DiseaseRecruiting
Est. primary completion 2027-12-30 · NCT06297096 · CT.gov ↗
What to watch
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2027-12-31 · NCT07589634 · CT.gov ↗
What to watch
2028 (20)
January 2028 (2)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic Leukemia, Richter's TransformationRecruiting
Est. primary completion 2028-01-15 · NCT06043674 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Diffuse Large B-cell LymphomaActive not recruiting
Est. primary completion 2028-03-31 · NCT04408638 · CT.gov ↗
What to watch
June 2028 (2)
Phase 3Antibody-mediated RejectionActive not recruiting
Est. primary completion 2028-06 · NCT04561986 · CT.gov ↗
What to watch
Phase 3COVID-19Recruiting
Est. primary completion 2028-06 · NCT02735707 · CT.gov ↗
What to watch
July 2028 (5)
Phase 2Treatment-Resistant Major Depressive DisorderNot yet recruiting
Est. primary completion 2028-07-01 · NCT07052058 · CT.gov ↗
What to watch
Phase 3Advanced CancerNot yet recruiting
Est. primary completion 2028-07-03 · NCT07929051 · CT.gov ↗
What to watch
Phase 1Leukemia Acute Myeloid - AMLNot yet recruiting
Est. primary completion 2028-07-10 · NCT07392814 · CT.gov ↗
What to watch
Phase 1Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral IschemiaRecruiting
Est. primary completion 2028-07-30 · NCT06863480 · CT.gov ↗
What to watch
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2028-07-31 · NCT05583617 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2SepsisRecruiting
Est. primary completion 2028-08-09 · NCT06381661 · CT.gov ↗
What to watch
Phase 1Rheumatoid ArthritisActive not recruiting
Est. primary completion 2028-08-29 · NCT05869955 · CT.gov ↗
What to watch
September 2028 (3)
Phase 1/2Chronic Granulomatous Disease (CGD)Enrolling by invitation
Est. primary completion 2028-09-01 · NCT07113743 · CT.gov ↗
What to watch
Phase 3COVID-19Recruiting
Est. primary completion 2028-09-30 · NCT04381936 · CT.gov ↗
What to watch
Early phase / not applicableCerebral Venous ThrombosisRecruiting
Est. primary completion 2028-09-30 · NCT07801638 · CT.gov ↗
What to watch
October 2028 (2)
Phase 3Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated VasculitisRecruiting
Est. primary completion 2028-10 · NCT04871191 · CT.gov ↗
What to watch
Phase 1/2Granulomatous Lobular Mastitis, Granulomatous MastitisNot yet recruiting
Est. primary completion 2028-10-30 · NCT07595900 · CT.gov ↗
What to watch
November 2028 (2)
Phase 3Systemic SclerosisNot yet recruiting
Est. primary completion 2028-11-14 · NCT07335562 · CT.gov ↗
What to watch
Phase 1Multiple MyelomaActive not recruiting
Est. primary completion 2028-11-15 · NCT06934044 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-12-21 · NCT04910568 · CT.gov ↗
What to watch
2029 (12)
January 2029 (2)
Phase 2Lung TransplantRecruiting
Est. primary completion 2029-01-08 · NCT06033196 · CT.gov ↗
What to watch
Phase 2/3Acute Ischemic StrokeNot yet recruiting
Est. primary completion 2029-01-31 · NCT07870681 · CT.gov ↗
What to watch
March 2029 (2)
Phase 1Refractory Autoimmune DiseasesRecruiting
Est. primary completion 2029-03-15 · NCT07115745 · CT.gov ↗
What to watch
Phase 1/2Non-Hodgkin's LymphomaActive not recruiting
Est. primary completion 2029-03-30 · NCT03075696 · CT.gov ↗
What to watch
April 2029 (2)
Phase 2Multiple MyelomaRecruiting
Est. primary completion 2029-04-13 · NCT07825064 · CT.gov ↗
What to watch
Phase 1Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2029-04-30 · NCT05169515 · CT.gov ↗
What to watch
May 2029 (2)
Phase 3Polyarticular Course Juvenile Idiopathic Arthritis (JIA)Recruiting
Est. primary completion 2029-05-30 · NCT06654882 · CT.gov ↗
What to watch
Phase 1/2Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory MarkersNot yet recruiting
Est. primary completion 2029-05-31 · NCT07889232 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2029-07-31 · NCT07643038 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Multiple Myeloma (MM), Multiple Myeloma Refractory, Multiple Myeloma in Relapse, Multiple MyelomaRecruiting
Est. primary completion 2029-10 · NCT07637578 · CT.gov ↗
What to watch
November 2029 (2)
Phase 1MelanomaNot yet recruiting
Est. primary completion 2029-11-01 · NCT07838974 · CT.gov ↗
What to watch
Phase 1/2Mature B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
2030 (6)
March 2030 (3)
Phase 1CalciphylaxisNot yet recruiting
Est. primary completion 2030-03 · NCT07708038 · CT.gov ↗
What to watch
Phase 1Lupus Erythematosus, SystemicRecruiting
Est. primary completion 2030-03-29 · NCT07629583 · CT.gov ↗
What to watch
Phase 3New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)Not yet recruiting
Est. primary completion 2030-03-31 · NCT07281027 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1AQP4+ NMOSDNot yet recruiting
Est. primary completion 2030-08-01 · NCT07573332 · CT.gov ↗
What to watch
September 2030 (2)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2030-09-06 · NCT04246086 · CT.gov ↗
What to watch
Phase 1/2Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
2031 (3)
February 2031 (2)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2031-02-06 · NCT07493317 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruiting
Est. primary completion 2031-02-10 · NCT05091424 · CT.gov ↗
What to watch
July 2031 (1)
Phase 1Ovarian Neoplasms, Endometrial NeoplasmsNot yet recruiting
Est. primary completion 2031-07-05 · NCT07870278 · CT.gov ↗
What to watch
2032 (1)
April 2032 (1)
Phase 2Mantle Cell Lymphoma, Mantle Cell Lymphoma RefractoryRecruiting
Est. primary completion 2032-04 · NCT05833763 · CT.gov ↗
What to watch
2033 (2)
October 2033 (1)
Phase 2/3B-cell Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2033-10-18 · NCT07570173 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic MalignanciesRecruiting
Est. primary completion 2033-11-16 · NCT07709000 · CT.gov ↗
What to watch
2042 (1)
November 2042 (1)
Phase 1Cholangiocarcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic AdenocarcinomaRecruiting
Est. primary completion 2042-11 · NCT07594067 · CT.gov ↗
What to watch

See the full readout calendar ↗